BRIDGEWATER, NJ -- (Marketwire) -- 11/19/12 -- Next week Elsevier Business Intelligence will host the 7th Annual Therapeutic Area Partnerships (TAP) at The Westin Copley Place in Boston on Nov. 28-30, 2012. TAP is the most efficient partnering meeting for biopharmaceutical companies and executives seeking to understand, within their therapeutic area portfolio, the strategic outlook for new products in development, alliance opportunities, and current industry pipeline needs and future projections.

One of the six therapeutic areas featured at the conference, oncology remains by far the largest and most active deal-making space in the biopharmaceutical industry. While many new drugs will reach the market in the next few years, existing blockbusters and other widely used agents will soon go generic, potentially impacting reimbursement and uptake for novel medications. Emerging diagnostic biomarkers, immunotherapies and conjugated biological therapies have the potential to transform the way patients are treated. The fast-changing oncology landscape and its implications for the industry will be the subject of a roundtable of oncology business development leaders from four major global pharmaceutical firms guided by an expert team from Campbell Alliance, an industry leader in biopharmaceutical and medical technology consulting and part of inVentiv Health.

The oncology-specific segments of TAP include a panel discussion and presentation of the Top Projects to Watch. The panel, including executives from AstraZeneca, Genentech, EMD Serono and Sanofi, will give attendees actionable intelligence on the trends, hurdles and opportunities that will shape the future of oncology drug development, alliances, and commercialization.

The Top Projects to Watch in oncology were hand-picked by the Campbell Alliance team based on their likelihood of success as future products. The companies confirmed to present their oncology projects this year are:

"The next decade in oncology will see newer classes of agents added to the treatment armamentarium," said Guru Muralimohan, engagement manager at Campbell Alliance. "Cytotoxics will become smarter and more targeted. Immunotherapies will produce a new wave of blockbusters as they leverage the human body's own immune system to help combat cancer. And, next generation agents targeting cancer cell metabolism will have the potential for disruptive change in the oncology treatment paradigm."

"These ten assets represent the leading edge of this sea change in oncology, and were chosen through an exhaustive process that took into account a variety of factors," added Jonathan Betts, Engagement Manager at Campbell Alliance. Such factors included what key opinion leaders have defined as the most promising mechanistic approaches and emerging trends based on Campbell Alliance's 2012 Dealmakers' Intentions Survey as well as the firm's understanding of areas of high current licensing activity within oncology and knowledge gained through assisting multiple companies develop oncology strategies.

Both Muralimohan and Betts will co-present the oncology Top Projects to Watch.

TAP is a one-of-a-kind opportunity to assess some of the most promising drugs in development and available for partnering in Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious Diseases, Autoimmune/Anti-Inflammatory Diseases, and Hot Space. Attracting the highest concentration of senior-level biotechnology and pharmaceuticals executives, TAP has come to be regarded as one the most productive, results-oriented deal-making conferences in the industry. For more information, or to register for this event, visit www.tapartnerships.com.

About Elsevier Business IntelligenceElsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.

About Elsevier Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, hel...

"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON...

In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designin...

You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected ...